scout
News|Videos|November 7, 2025

Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer

Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME